Atossa Therapeutics, Inc. (ATOS)

Market Cap	101.62M
Revenue (ttm)	n/a
Net Income (ttm)	-24.30M
Shares Out	126.62M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	94,963
Open	0.820
Previous Close	0.801
Day's Range	0.787 - 0.820
52-Week Range	0.500 - 1.620
Beta	1.13
Analysts	Buy
Price Target	5.10 (+535.51%)
Earnings Date	Feb 27, 2023

About ATOS

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-1...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2012
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: ATOS

Analyst Forecast

According to 8 analysts, the average rating for ATOS stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 535.51% from the latest price.

Price Target

$5.1

(535.51% upside)

Analyst Consensus: Buy